I’m tempted towards optimism too, in regards to iPPS impact on the synovium. We’ll have to wait and see, but I can see the logic behind your theory. I also think I detect confidence from Paul around 008 in the recent interview with Scott Williams. There’s no smoke without fire, and i’m glad you mentioned Happell because when I was reading I kept coming back to his simple question, along the lines of....”How could I go years without pain, and be able to do things I couldn’t do before, if the drug is not disease-modifying?”
We’ve discussed the impact DMOAD verification could have on PARs future, and it all makes Q3 2021 a very exciting near-term event for holders. The lift in market sentiment often pre-empts such an event, and I believe it will this time too. However, whereas in some cases we see a sell-off upon confirmation of anticipated news - I most certainly do not believe this will be the case if we see compelling clinical DMOAD evidence later this year. In that event, we go straight through the looking glass.
PAR Price at posting:
$2.64 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)